Back to Search Start Over

SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?

Authors :
Guisado Hernández, Paloma
Blanco Lobo, Pilar
Villaoslada, Isabel
de Felipe, Beatriz
Lucena, José M.
Martín Gutierrez, Guillermo
Castro, María José
Gutiérrez Valencia, Alicia
Sánchez Codez, María Isabel
Gaboli, Mirella
Neth, Olaf
Olbrich, Peter
Source :
Journal of Clinical Immunology; Oct2021, Vol. 41 Issue 7, p1502-1506, 5p
Publication Year :
2021

Abstract

Non-stimulated STAT1 levels in CD8+ T cells before and during SARS-CoV-2 infection (A); pSTAT1 levels in CD8 + T cells pre- and post-stimulation with IFN before and during SARS-CoV-2 infection (B). In addition, serum levels of IL6, IFN , and CXCL10 were elevated during infection, supporting the ability of the patient to develop an inflammatory response even under ruxolitinib therapy. Although increased total STAT1 levels were documented, hyperphosphorylation of STAT1 was not observed during the complete follow-up, proposing ruxolitinib to be effective in controlling cytokine hyperresponsiveness typically found in STAT1 GOF patients, even in the context of SARS-CoV-2 infection. [Extracted from the article]

Details

Language :
English
ISSN :
02719142
Volume :
41
Issue :
7
Database :
Complementary Index
Journal :
Journal of Clinical Immunology
Publication Type :
Academic Journal
Accession number :
152535155
Full Text :
https://doi.org/10.1007/s10875-021-01081-9